Discover BREXAFEMME
NOW FDA APPROVED: BREXAFEMME® (ibrexafungerp tablets) is the first and only oral non-azole treatment of its kind
Discover BREXAFEMME
Novel Anti-Infective Treatments
We are pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead asset, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. On June 1, 2021, ibrexafungerp received its first FDA approval as an oral antifungal product with the trade name BREXAFEMME®.
Learn more about BREXAFEMME®
Ibrexafungerp: A Versatile Anti-Infective
Latest News
Committed to Helping Patients Overcome and Prevent Difficult-to-Treat Infections
Our team strives to save and improve patients' lives by advancing a novel broad-spectrum antifungal therapy to address difficult-to-treat and often life-threatening infections, and to transforming the anti-infective treatment paradigms for patients worldwide.
More About Us
Our Innovative Antifungal Platform
Our lead asset, ibrexafungerp (formerly known as SCY-078), is an investigational antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, known as triterpenoids.
Our Science Our Pipeline
Success Backed by Strong Leadership
The innovation that drives our science and pipeline is a direct reflection of our leadership's commitment to bringing ibrexafungerp to patients in need, and ability to advance the product across multiple indications from discovery through to the commercial stage. This leadership has a proven track record and deep antifungal expertise needed to advance ibrexafungerp to commercialization.
Leadership Board of Directors